Higher immune responses were elicited by mRNA-1083 than high-dose quadrivalent inactivated influenza vaccine for all 4 influenza strains and high-dose quadrivalent inactivated influenza vaccine for 3 ...
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical ...
As of May 2023, the WHO recommends the use of a monovalent XBB.1 descendent lineage, such as omicron XBB.1.5, as the vaccine antigen for COVID-19 vaccines. However, BA.2.86 and its descendent lineages ...
CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has authorized its updated COVID-19 mRNA vaccine, Spikevax®, targeting the SARS-CoV-2 LP.8.1 variant, for ...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate ...
mRNA-1083 induced higher immune responses than recommended standard-care influenza and COVID-19 vaccines. (HealthDay News) — mRNA-1083 vaccine is noninferior and induces higher immune responses than ...
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results